DBV Technologies Analyst Ratings
HC Wainwright & Co. Maintains Buy on DBV Technologies, Lowers Price Target to $5
Optimistic Buy Rating for DBV Technologies With Viaskin's Market Potential and Regulatory Prospects
Buy Rating Affirmed for DBV Technologies SA Amidst Strong Clinical Progress and Solid Financial Footing
Buy Rating Affirmed for DBV Technologies on Viaskin Patch Development and Positive Trial Outcomes
Positive Clinical and Financial Projections for DBV Technologies Reinforce Buy Rating
Buy Rating Affirmed for DBV Technologies on Strong Viaskin Peanut Patch Clinical Data and Promising Trials
DBV Technologies Analyst Ratings
JMP Securities Keeps Their Buy Rating on DBV Technologies SA – American (DBVT)
Buy Rating for DBV Technologies: Viaskin Peanut's Market Edge Over Xolair
Buy Rating Affirmed for DBV Technologies Amid Reduced Competition and Promising Clinical Progress
HC Wainwright & Co. Reiterates Buy on DBV Technologies, Maintains $10 Price Target
DBV Technologies Analyst Ratings
Positive EPITOPE Trial Results Bolster Viaskin's Potential: DBV Technologies SA Receives Buy Rating
Goldman Sachs Maintains Sell on DBV Technologies, Lowers Price Target to $1
DBV Technologies Analyst Ratings
DBV Technologies Receives Buy Rating: Efficacy and Safety of Viaskin Patch Backed by Consistent FDA Communications and Successful Trials
Analysts Offer Insights on Healthcare Companies: ImmunoGen (IMGN), DBV Technologies SA – American (DBVT) and CymaBay Therapeutics (CBAY)
HC Wainwright & Co. Reiterates Buy on DBV Technologies, Maintains $10 Price Target
DBV Technologies Analyst Ratings
No Data